Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Dr. Stephen R. Grobmyer completed his fellowship in surgical oncology at Memorial Sloan Kettering Cancer Center in 2004. Formerly, the Edward M. Copeland III Chair in Surgical Oncology at University of Florida; in 2012 he became Section Head of Surgical Oncology and Director of the Breast Center at Cleveland Clinic in Cleveland, Ohio. He currently is Professor of Surgery at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He is co-leader of the Cleveland Clinic Comprehensive Breast Cancer Program.
Dr. Grobmyer is an expert in the management of breast cancer. He has extensive experience with skin sparing and nipple sparing mastectomy for selected breast cancer patients. He has a particular focus on the surgical management of patients with high risk genetic mutations for breast cancer. He also has extensive experience with sentinel node biopsy, axillary reverse mapping to reduce lymphedema. He has also an interest in recurrent breast cancer and breast angiosarcoma.
Dr. Grobmyer is regarded as an international leader in the use of single dose intra-operative radiation therapy for early stage breast cancer patients. He was senior author on the largest series of patients treated with intraoperative radiation therapy for breast cancer in North America. He serves on the Board of Directors for the TARGIT-US, a multi-institutional prospective study of intraoperative radiation therapy, and on the Board of Directors for the TARGIT Collaborative Group. He is course director for the North American TARGIT Academy at Cleveland Clinic.
Dr. Grobmyer has been elected to Best Doctors in America every year consecutively since 2007 and was recognized among “Best Doctors” in Cleveland in 2013-2015. Nationally, he has served on the American Society of Clinical Oncology Breast Cancer Education Committee, and he was formerly as scientific program committee chair for the Society of Surgical Oncology. He has served on the breast cancer advisory committee for the American Board of Surgery and serves on the editorial board of The European Journal of Surgical Oncology, The Annals of Surgical Oncology, and The Breast Journal. He is an active member of the Southern Surgical Association, Central Surgical Association, Society of Surgical Oncology, American College of Surgeons, American Society of Clinical Oncology, and American Society of Breast Surgeons. He has given over 100 invited lectures nationally and internationally.
Dr. Grobmyer’s innovative research focuses on developing new approaches to prevent, diagnose and treat breast cancer. He has published over 150 peer reviewed manuscripts, 16 book chapters and edited a textbook on innovative cancer therapies. He is currently the editor for the Breast Cancer Section for Society of Surgical Oncology’s Complex General Surgical Oncology. He has been the recipient of numerous prestigious awards including: The Lester Dragstedt Physician Scientist Award, The Society of Surgical Oncology Clinical Investigator Award, and The American College of Surgeons Japan Travelling Fellowship. His influential research has been featured nationally on NBC Nightly News, MSNBC, National Public Radio, The New York Times and Vogue.
Surgical oncology, breast cancer
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 12/10/2015, Dr. Grobmyer has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.